PriceTargets.com logo

Cybin - CYBN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 2,067.63%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.35 As of 04/25/2024 01:00 AM ET
▼ -0.01 (-2.81%)

This chart shows the closing price for CYBN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cybin Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYBN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYBN

Analyst Price Target is $7.50
▲ +2,067.63% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cybin in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 2,067.63% upside from the last price of $0.35.

This chart shows the closing price for CYBN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Cybin. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
8/11/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$6.00 ➝ $5.00
6/28/2023500.comReiterated RatingReiterates
3/10/2023HC WainwrightReiterated RatingBuy$10.00
2/15/2023HC WainwrightReiterated RatingBuy$10.00
2/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$3.00
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$3.00
11/21/2022Stifel NicolausLower TargetC$3.00 ➝ C$1.50
11/17/2022HC WainwrightReiterated RatingBuy$10.00
8/24/2022Stifel NicolausLower TargetC$8.25 ➝ C$3.00
6/30/2022HC WainwrightReiterated RatingBuy$10.00
6/7/2022Roth CapitalReiterated RatingBuy
4/14/2022OppenheimerReiterated RatingBuy$10.00
11/23/2021Stifel NicolausLower TargetBuyC$10.00 ➝ C$8.25
11/22/2021HC WainwrightBoost TargetPositive ➝ Buy$8.00 ➝ $10.00
11/19/2021Maxim GroupDowngradeBuy ➝ Hold
11/9/2021Stifel NicolausLower TargetBuyC$15.00 ➝ C$10.00
10/4/2021OppenheimerInitiated CoverageOutperform$7.00
8/26/2021Cantor FitzgeraldInitiated CoverageOverweight$9.00
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Cybin logo
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $0.35
Low: $0.34
High: $0.35

50 Day Range

MA: $0.39
Low: $0.32
High: $0.46

52 Week Range

Now: $0.35
Low: $0.21
High: $0.74

Volume

2,955,743 shs

Average Volume

5,088,969 shs

Market Capitalization

$142.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Cybin?

The following Wall Street sell-side analysts have issued stock ratings on Cybin in the last year: 500.com Limited, Canaccord Genuity Group Inc., and HC Wainwright.
View the latest analyst ratings for CYBN.

What is the current price target for Cybin?

2 Wall Street analysts have set twelve-month price targets for Cybin in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 2,067.6%. HC Wainwright has the highest price target set, predicting CYBN will reach $10.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $5.00 for Cybin in the next year.
View the latest price targets for CYBN.

What is the current consensus analyst rating for Cybin?

Cybin currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYBN will outperform the market and that investors should add to their positions of Cybin.
View the latest ratings for CYBN.

What other companies compete with Cybin?

Other companies that are similar to Cybin include NGM Biopharmaceuticals, Kinnate Biopharma, Biopharmx, NervGen Pharma and Ampliphi Biosciences. Learn More about companies similar to Cybin.

How do I contact Cybin's investor relations team?

Cybin's physical mailing address is 100 KING STREET WEST SUITE 5600, TORONTO A6, ON M5X 1C9. The company's listed phone number is (866) 292-4601 and its investor relations email address is [email protected]. The official website for Cybin is www.cybin.com. Learn More about contacing Cybin investor relations.